[DOI] [PMC free article] [PubMed] [Google Scholar] 92.Bocsan I.C., Mgureanu D.C., Pop R.M., Levai A.M., Macovei .O., Ptraca I.M., Chedea V.S., Buzoianu A.D
Administration of exogenous carnitine as an adjunct to VPA therapy is thought to restore beta-oxidation to mitochondria cells of the liver, accept toxic acyl moieties from CoA, and relieve the inhibition of urea synthesis.[3] However, our findings suggested that the effective utilization of levocarnitine transport into mitochondria, which may be individually different, might play an important role to lead these favorable processes
Association between MTHFR C677T polymorphism and neural tube defect risks: A comprehensive evaluation in three groups of NTD patients, mothers, and fathers
The pharmacology beneath the trade-off At the receptor level, the two peptides converge on secretion through different systems